Secondary analysis of TRANSFORM (136 patients, second-line large B-cell lymphoma): ctDNA clearance predicted longer event-free survival at all time points with liso-cel or ASCT; more liso-cel patients achieved ctDNA clearance.
Secondary analysisn = 136
Stepan et al. Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy